Skip to main content
Log in

Low-dose idebenone treatment in Friedreich’s ataxia with and without cardiac hypertrophy

  • Original Communication
  • Published:
Journal of Neurology Aims and scope Submit manuscript

Abstract

Left ventricular hypertrophy (LVH) is a frequent finding in Friedreich’s ataxia (FRDA). In previous studies treatment with idebenone, a synthetic analogue of coenzyme Q10, has been associated with a substantial decrease in myocardial hypertrophy, despite great variability in cardiac responsiveness among patients. Here we present the results of a retrospective analysis of a cohort of 35 patients (20 with LVH, 15 without LVH) with confirmed molecular diagnosis of FRDA, treated with idebenone 5 mg/kg/day for up to five years. At the end of the study, we found an increase of interventricular septum and posterior wall thickness in the group without LVH before treatment and no change in the group with LVH before treatment. The neurological picture of the disease significantly deteriorated with time in both groups.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Artuch R, Aracil A, Mas A et al (2002) Friedreich ataxia: idebenone treatment in early stage patients. Neuropediatrics 33:190–193

    Article  PubMed  CAS  Google Scholar 

  2. Buyse G, Mertens L, Di Salvo G et al (2003) Idebenone treatment in Friedreich’s ataxia: neurological, cardiac, and biochemical monitoring. Neurology 60:1679–1681

    Article  PubMed  CAS  Google Scholar 

  3. Campuzano V, Montermini L, Moltò MD et al (1996) Friedreich’s ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 271:1423–1427

    Article  PubMed  CAS  Google Scholar 

  4. Di Prospero NA, Baker A, Jeffries N, Fishbeck KN (2007) Neurological effects of high dose idebenone in patients with Friedreich’s ataxia: a randomized, placebo-controlled trial. Lancet Neurol 6:878–886

    Article  PubMed  CAS  Google Scholar 

  5. Dutka DP, Donnelly JE, Palka P, Lange A, Nunez DJ, Nihoyannopoulos P (2000) Echocardiographic characterization of cardiomyopathy in Friedreich’s ataxia with tissue Doppler echocardiographycally derived myocardial velocity. Circulation 102:1276–1282

    PubMed  CAS  Google Scholar 

  6. Filla A, De Michele G, Caruso G, Marconi R, Campanella G (1990) Genetic data and natural history of Friedreich’s disease: a study of 80 Italian patients. J Neurol 237:345–351

    Article  PubMed  CAS  Google Scholar 

  7. Gillis JC, Benefield P, McTavish D (1994) Idebenone: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in age-related cognitive disorders. Drug Aging 5:133–152

    Article  CAS  Google Scholar 

  8. Harding AE (1981) Friedreich’s ataxia: a clinical and genetic study of 90 families with analysis of early diagnostic criteria and intrafamiliar clustering of clinical features. Brain 104:589–620

    Article  PubMed  CAS  Google Scholar 

  9. Henry WL, Gardin JM, Ware JH (1980) Echocardiographic measurements in normal subjects from infancy to old age. Circulation 62:1054–1061

    PubMed  CAS  Google Scholar 

  10. Mariotti C, Solari A, Torta D, Marano L, Fiorentini C, Di Donato S (2003) Idebenone treatment in Friedreich patients: one-year-long randomized placebo controlled trial. Neurology 60:1676–1679

    PubMed  CAS  Google Scholar 

  11. Meyer C, Schmid G, Gorlitz S, Ernst M, Wilkens C, Wilhelms I et al (2007) Cardiomyopathy in Friedreich’s ataxia—assessment by cardiac MRI. Mov Disord 22(11):1615–1622

    Article  PubMed  Google Scholar 

  12. Pineda M, Arpa J, Montero R, Aracil A, Dominguez F, Galvan M, Mas a, Martorell L et al (2008) Idebenone treatment in paediatric and adult patients with Friedreich ataxia: long term follow-up. Eur J Paediatr Neurol 12(6):470–475

    Article  PubMed  Google Scholar 

  13. Ribai P, Pousset F, Tanguy ML, Rivaud-Pechoux S, Le Ber I, Gasparini F, Charles P, Bèreaud AS et al (2007) Neurological, cardiological and oculomotor progression in 104 patients with Friedreich’s ataxia during long-term follow up. Arch Neurol 64:558–564

    Article  PubMed  Google Scholar 

  14. Rotig A, de Lonlay P, Chretien D, Foury F, Koenig M, Sidi D, Munnich A, Rustin P (1997) Aconitase and mitochondrial iron–sulphur protein deficiency in Friedreich ataxia. Mol Cell Biochem 174:215–217

    Article  Google Scholar 

  15. Rustin P, Rotig A, Munnich A, Sidi D (2002) Heart hypertrophy and function are improved by idebenone in Friedreich’s ataxia. Free Radic Res 36:467–469

    Article  PubMed  CAS  Google Scholar 

  16. Steinsapir K, Lewis W (1985) Dilated cardiomyopathy associated with Friedreich’s ataxia. Arch Pathos Lab Med 109:454–456

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to C. Rinaldi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rinaldi, C., Tucci, T., Maione, S. et al. Low-dose idebenone treatment in Friedreich’s ataxia with and without cardiac hypertrophy. J Neurol 256, 1434–1437 (2009). https://doi.org/10.1007/s00415-009-5130-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-009-5130-6

Keywords

Navigation